Aurora Spine to Present at Brean Capital Life Sciences Summit Conference

Aurora Spine Corporation (TSX VENTURE:ASG) announced today that it will be presenting at the Brean Capital Life Sciences Summit Conference in New York, NY on November 24, 2014. Brean Capital's Corporate Access product offering includes a number of industry-specific and regional "best idea" investment conferences to facilitate the interaction of company management and institutional investors throughout the year.

"We are excited to be participating in the Brean Capital Life Sciences Summit Conference in New York," said Eric Fronk, Chief Financial Officer of Aurora Spine. "This is a great opportunity to share our company's goals and mission in providing advanced spinal technologies in the medical industry. This year we are proud to showcase several FDA cleared products and procedures, all designed to improve spine patient outcomes, drive continued surgeon interests, and provide unique benefits that deliver value to hospitals and patients."

The goal of each conference is to provide institutional investors with high-level access to senior management and industry experts and designed to connect the dots and provide original outlook and depth.

About Aurora Spine

Aurora Spine is an early stage company focused on bringing new solutions to the spinal implant market through a series of screwless, innovative, minimally invasive, regenerative spinal implant technologies. Aurora Spine recently obtained its 5th FDA clearance in the past 11 months and continues to position itself at the forefront of spinal surgery procedures, focusing on minimally invasive spine surgery technologies. Aurora Spine is changing spine surgery by focusing on disruptive technologies following the Company's commitment to - Simplifying the Complex.

Forward-Looking Statements

This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company's products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.

Aurora Spine Corporation

Trent Northcutt

President and Chief Executive Officer

(760) 424-2004

Eric Fronk

Chief Financial Officer

(760) 424-2004

Christian Flores